About Affimed
Innovative antibody platform and product company
Company Profile
Affimed is a clinical stage biotech company developing unique antibody therapeutics for improved treatments of cancer and inflammatory diseases. We have generated a comprehensive pipeline of antibody product candidates based on our proprietary TandAb® technology platform.
Our TandAb® molecules are human antibodies with excellent binding properties and product stability. These antibody formats promise increased therapeutic potential and superior safety profiles compared to monoclonal antibodies. Furthermore, when compared to antibody fragments and scaffolds, TandAbs® have a much longer half-life. Robust GMP production and downstream processes have been established with renowned partners.
Affimed´s lead product candidates focus on well established targets in lymphoma indications.
- AFM13 entered a phase I clinical trial in 2010 in order to assess its safety and tolerability in Hodgkin Lymphoma patients. In the first dosing levels, the drug appears to be safe and well tolerated. Orphan Drug Designation was granted in 2009 for both the US and Europe.
- AFM11 and AFM12 to treat Non-Hodgkin Lymphoma are currently in late stage preclinical development and are expected to begin clinical studies in 2011.
- Further novel product candidates for the treatment of solid tumors and inflammatory diseases are in development.
Founded in 2000 as a spin-off from DKFZ
Affimed was founded in 2000 as a spin-off from the German Cancer Research Centre (DKFZ) in Heidelberg. Today, Affimed employs twenty-six staff. We are backed by a peer group of investors including, aeris CAPITAL, BioMed Invest, Life Sciences Partners, Novo Nordisk A/S, and Orbimed.